Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points

• Main Authors: Jinmei Su (Author), Mengtao Li (Author), Lan He (Author), Dongbao Zhao (Author), Weiguo Wan (Author), Yi Liu (Author), Jianhua Xu (Author), Jian Xu (Author), Huaxiang Liu (Author), Lindi Jiang (Author), Huaxiang Wu (Author), Xiaoxia Zuo (Author), Cibo Huang (Author), Xiumei Liu (Author), Fen Li (Author), Zhiyi Zhang (Author), Xiangyuan Liu (Author), Lingli Dong (Author), Tianwang Li (Author), Haiying Chen (Author), Jingyang Li (Author), Dongyi He (Author), Xin Lu (Author), Anbin Huang (Author), Yi Tao (Author), Yanyan Wang (Author), Zhuoli Zhang (Author), Wei Wei (Author), Xiaofeng Li (Author), Xiaofeng Zeng (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objectives: A phase III, 24-weeks Chinese clinical trial demonstrated that efficacy and safety outcomes of treatments with 40 mg/0.8 ml HS016 (n = 416) or adalimumab (n = 232) for active ankylosing spondylitis (AS) patients was comparable. In the present study, a subanalysis of the clinical trial wa...